 | | Forward email to a friend. | | | | | | | | | | New Profiled Company - YFRM | | | Valued Subscribers, Welcome New Members, Did you do the research on YFRM yet? We hope you followed our alert because the company just issued more hot news! This is straight off the press! Before we look at the news, let`s dig into some facts. Right now, YFRM is at a low price of only .25 cents. If it hits upwards of the half dollar level soon, we are talking about a double up for our members in today's session! Check out this news release. YaFarm Technologies Announces ISCI Clinical Study PITTSTON, ME--(Marketwire - Feb 25, 2013) - YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) announced today that the Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies, has initiated its first clinical study in Degenerative Neuromuscular Diseases (DNMD). The clinical studies will be conducted at the ISCI facility in the Hospital Galenia in Cancun, Mexico and will consist of an integrative approach that will combine autologous, adult progenitor (stem) cells with physical therapy, nutrition and other complementary treatments to multiple sclerosis (MS), Alzheimer's and Parkinson's disease. Patients will spend up to three weeks in Cancun for the therapies. The patient's own cells will be processed in the ISCI's state-of-the-art laboratory with a class 10,000, ISO 7 clean room. As part of the study protocol all patients will have to meet a strict set of inclusion and exclusion criteria and be evaluated by a 3rd party physician prior to treatment who will also serve to provide long-term and independent collection of outcome data, and the reporting of any adverse event or complication stemming from the treatment. "Today there are literally hundreds of thousands of people living with DNMD," says David Audley, CEO of the ISCI. "Estimates from the National Institutes of Health provide a grim reminder to what many already know: these diseases touch many people." The National Institutes for Neurological Disorders and Stroke (NINDS) estimates that there are currently 250,000 people in the US alone with MS(1), while the University of Kansas Institute for Neurological Discoveries believes that Parkinson's disease affects nearly 1.5 million(2) and the National Institutes for Aging estimates that over 5 million Americans may suffer from Alzheimer's.(3) "And while conventional medicine may provide relief for many," continues Mr Audley, "Thousands of others find themselves suffering with limited or no options for treatment. It is for these patients that we have initiated these studies." YFRM’s first clinical study regarding this disease type is a major step for the company that presents them with potential for unimaginable shareholder confidence. All evidence from news to technical analysis to consistent volume supports our strong belief that investors are bound to witness solid returns on investment from current trading levels! This is a huge start for 2013 and with what the company brings to the table we believe there could be much more to come! | | | | | DISCLAIMER | | | Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Full disclaimer can be read at: http://www.bullexchange.com/disclaimer
PLEASE NOTE WELL: The Bullexchange.com employees are not Registered as an Investment Advisers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold Bullexchange.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur.
We are engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Bullexchange.com’s sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Bullexchange.com or an offer or solicitation to buy or sell any security. Neither the owner of Bullexchange.com nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit Bullexchange.com. Bullexchange.com makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors.
Notice of Compensation
Please be advised that Bullexchange.com receives compensation to perform promotional and advertising services for companies mentioned on our website, social media platforms, & our emails by third parties. The Bullexchange.com and or its affiliates have NOT received any compensation to date for investor communications services but expects to receive $100,000 from a third party non affiliate for two months of coverage. Bullexchange.com receives compensation as a production budget for advertising efforts and will retain amounts over and above the cost of production, copy writing services, mailing and other distribution expenses as a fee for our services.
Notice of Stock Price Movements and Volatility
Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week.
Notice of Affiliated and Non-Affiliated Newsletters
Bullexchange.com regularly shares research with other affiliated newsletters ("Affiliated Newsletters"). It is also possible that other newsletters or profiles have been created by sources we are unaware of. Viewers should take this into consideration when viewing any increased interest in companies mentioned.
Because we receive monetary or securities compensation, most often in the form of common stock (hereafter referred to as the "Shares") for our dissemination of publicly disseminated information (the “Information”) regarding various issuers of securities, we disclose our specific compensation herein and in our individual reports of profiled issuers. It is imperative that all readers visit Bullexchange.com’s full disclaimer (http://www.bullexchange.com/disclaimer) for compensations disclosure and carefully review our Disclaimer in its entirety, which contains important information about penny stocks, our operations, the limited nature of the Information and various risks attendant to the companies that we profile, including that: (a ) we receive our compensation in free trading shares, which we will sell immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time; as a result, our selling activities will cause significant volatility in the Issuer’s stock price and/or significantly depress the Issuer’s stock price; (b) we will buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which will cause significant volatility in the Issuer’s stock price and/or significantly depress or increase the Issuer’s stock price; (c) there is an inherent and actual conflict of interest that exists between our Readers’ interests and our interests because we: (i) receive the Shares as compensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including a t the same time the Information is being disseminated or shortly thereafter or at any time; and (ii) buy and sells the Profiled Company’s shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time. Our gains from sale of the Shares may be substantial. | | | | | | | | | | | This message was sent to to ignoble.experiment@arconati.us by
The Bull Exchange
The Bull Exchange8 Cothall #458 Roseau Valley, 00152
| | | | Unsubscribe | Newsletter settings | Forward to a friend |   | |
No comments:
Post a Comment
Keep a civil tongue.